The goal of this clinical trial is to learn more about the safety and effectiveness of investigational drug Mezigdomide when combined with approved treatments carfilzomib and dexamethasone compared to approved treatments carfilzomib and dexamethasone alone in participants with relapsed and refractory multiple myeloma.
This trial is currently open and accepting patients.
This study is being conducted in two different parts, or stages.
In Stage 1, there are four planned groups, also called arms. Three of the four arms will receive different dose levels of investigational drug mezigdomide in combination with approved treatments carfilzomib and dexamethasone, and one arm will receive approved treatments carfilzomib and dexamethasone.
In Stage 2, there are two planned arms. One arm will receive mezigdomide (at the selected dose determined by stage 1), Carfilzomib and Dexamethasone, and the other arm will receive Carfilzomib and Dexamethasone.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
Additional eligibility criteria apply and can be explained by the study doctor.
Enrollment: 525 patients (estimated)View More
View all clinical trial locations sorted by state.
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message